22 results
Thumbnail

D2.413 - Diagnostic Value of the Basophil Degranulation Test in High-Risk Drug-Induced Anaphylaxis

Thumbnail

D2.415 - DRESS Syndrome induced by Lenalidomide

Thumbnail

D2.407 - Treating Through in Pediatric Patients: A Single-Center Experience

Thumbnail

D2.408 - Hypersensitivity Reactions to Corticosteroids: A Retrospective Cohort Study

Thumbnail

D2.414 - Diagnostic Distribution of Patch, Delayed-Reading Intradermal, and Drug Provocation Tests in Delayed-Type Cutaneous Drug Hypersensitivity

Thumbnail

D2.416 - Skin reaction to Kaftrio/Kalydeco (CFTR) in cystic fibrosis: safe reintroduction using an outpatient desensitization protocol

Thumbnail

D2.418 - Tolperisone Hypersensitivity: An Underrecognized Drug Allergy in the Context of Widespread Off-Label Use

Thumbnail

D2.419 - DRESS syndrome in the context of carbamazepine treatment - case report

Thumbnail

D2.420 - A challenging case of cardiotoxicity following palbociclib therapy

Thumbnail

D2.471 - Efficacy of omalizumab in the treatment of chronic spontaneous urticaria in children

Thumbnail

D2.473 - Omalizumab as adjuvant therapy in drug desensitization to chemotherapy- a single Center experience

Thumbnail

D2.475 - Treatment delay and likelihood of remission on omalizumab in chronic spontaneous urticaria: a real-world observational study

Thumbnail

D2.464 - Stapokibart (anti–IL-4Rα monoclonal antibody) across type 2 inflammatory diseases in routine practice: a three-case series of severe atopic dermatitis, chronic urticaria with rhinosinusitis, and immune-related bullous pemphigoid

Thumbnail

D2.465 - Omalizumab Enhances Safety and Supports Completion of Oral Immunotherapy in High-Risk Patients

Thumbnail

D2.466 - More options for the treatment of Chronic Spontaneous Urticaria: Tezepelumab

Thumbnail

D2.467 - Management of Netherton syndrome and hereditary angioedema with concurrent biologic therapy: a novel case

Thumbnail

D2.468 - Real-world effectiveness and safety of dupilumab in pediatric atopic dermatitis: a retrospective cohort study

Thumbnail

D2.469 - Pre-switch perceptions of omalizumab biosimilar prefilled pen in pediatric allergy: a cross-sectional survey

Thumbnail

D2.470 - Potential Clinical and Laboratory Biomarkers for Predicting Omalizumab Response in Chronic Spontaneous Urticaria

Thumbnail

D2.472 - Immunology Innovation Program: Developing Antibodies Against Novel Targets Through Co-creation